Welcome to LookChem.com Sign In|Join Free
  • or
Medicarpin, also known as 7,12-dihydroxy-3-(4-methoxyphenyl)chromen-4-one, is a natural flavonoid compound found in various plant sources, including the seeds of the red clover (Trifolium pratense). It possesses antioxidant, anti-inflammatory, and immunomodulatory properties, making it a promising candidate for various applications in the pharmaceutical and healthcare industries.

32383-76-9

Post Buying Request

32383-76-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

32383-76-9 Usage

Uses

Used in Pharmaceutical Industry:
Medicarpin is used as an anti-inflammatory agent for its ability to inhibit the release of IL-8, a pro-inflammatory cytokine, via interactions with toll-like receptor 4 and lipopolysaccharide. This property makes it a potential candidate for the treatment of inflammatory diseases.
Used in Healthcare Industry:
Medicarpin is used as a potential therapeutic agent for the treatment of COVID-19. Its immunomodulatory and anti-inflammatory properties may help alleviate the symptoms and complications associated with the disease, providing a promising alternative or complementary treatment option to conventional therapies.

Check Digit Verification of cas no

The CAS Registry Mumber 32383-76-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,3,8 and 3 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 32383-76:
(7*3)+(6*2)+(5*3)+(4*8)+(3*3)+(2*7)+(1*6)=109
109 % 10 = 9
So 32383-76-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H14O4/c1-18-10-3-5-11-13-8-19-14-6-9(17)2-4-12(14)16(13)20-15(11)7-10/h2-7,13,16-17H,8H2,1H3/t13-,16-/m0/s1

32383-76-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (-)-medicarpin

1.2 Other means of identification

Product number -
Other names Demethylhomopterocarpin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:32383-76-9 SDS

32383-76-9Synthetic route

7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on
485-72-3

7-Hydroxy-3-(4-methoxy-phenyl)-chromen-4-on

medicarpin
32383-76-9

medicarpin

2,7-dihydroxy-4'-methoxyisoflavanone
770722-02-6

2,7-dihydroxy-4'-methoxyisoflavanone

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 2-hydroxyisoflavanone dehydratase
View Scheme
(2R,3S)-2,7,4'-trihydroxyisoflavanone
131887-80-4

(2R,3S)-2,7,4'-trihydroxyisoflavanone

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 2-methoxyethanol / 2,7,4'-trihydroxyisoflavanone 4'-O-methyltransferase
2: 2-hydroxyisoflavanone dehydratase
View Scheme
3-(2,4-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one
1891-01-6

3-(2,4-dimethoxyphenyl)-7-hydroxy-4H-chromen-4-one

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: aluminum (III) chloride / acetonitrile / 0 °C / Reflux
1.2: Cooling with ice
2.1: sodium tetrahydroborate / ethanol / 0 - 20 °C
3.1: Lux cellulose-1 PHENOMENIX column / acetonitrile; water / Resolution of racemate
View Scheme
7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-4H-chromen-4-one
1890-99-9

7-hydroxy-3-(2-hydroxy-4-methoxyphenyl)-4H-chromen-4-one

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium tetrahydroborate / ethanol / 0 - 20 °C
2: Lux cellulose-1 PHENOMENIX column / acetonitrile; water / Resolution of racemate
View Scheme
recorcinol
108-46-3

recorcinol

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: boron trifluoride diethyl etherate / 2 h / 90 - 100 °C
1.2: 50 - 90 °C
2.1: aluminum (III) chloride / acetonitrile / 0 °C / Reflux
2.2: Cooling with ice
3.1: sodium tetrahydroborate / ethanol / 0 - 20 °C
4.1: Lux cellulose-1 PHENOMENIX column / acetonitrile; water / Resolution of racemate
View Scheme
9-methoxy-6a,11a-dihydro-6H-benzo[4,5]furo[3,2-c]chromen-3-ol
32383-76-9, 33983-39-0, 33983-40-3, 57458-34-1

9-methoxy-6a,11a-dihydro-6H-benzo[4,5]furo[3,2-c]chromen-3-ol

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
With Lux cellulose-1 PHENOMENIX column In water; acetonitrile Resolution of racemate;A n/a
B n/a
2,4-dimethoxyphenylacetic acid
6496-89-5

2,4-dimethoxyphenylacetic acid

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: boron trifluoride diethyl etherate / 2 h / 90 - 100 °C
1.2: 50 - 90 °C
2.1: aluminum (III) chloride / acetonitrile / 0 °C / Reflux
2.2: Cooling with ice
3.1: sodium tetrahydroborate / ethanol / 0 - 20 °C
4.1: Lux cellulose-1 PHENOMENIX column / acetonitrile; water / Resolution of racemate
View Scheme
(2S,3R)-3-(2-hydroxy-4-methoxyphenyl)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)chroman-7-ol

(2S,3R)-3-(2-hydroxy-4-methoxyphenyl)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)chroman-7-ol

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: sodium hydride / N,N-dimethyl-formamide / 5 h / -78 - 20 °C / Inert atmosphere
2: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 2.17 h / -78 °C
3: lead(II,IV) oxide / benzene / 3 h / 85 °C
4: palladium 10% on activated carbon; hydrogen / ethanol
5: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
(2S,3R)-7-(benzyloxy)-3-(2-(benzyloxy)-4-methoxyphenyl)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)chroman

(2S,3R)-7-(benzyloxy)-3-(2-(benzyloxy)-4-methoxyphenyl)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)chroman

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 2.17 h / -78 °C
2: lead(II,IV) oxide / benzene / 3 h / 85 °C
3: palladium 10% on activated carbon; hydrogen / ethanol
4: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
(R)-7-(benzyloxy)-3-(2-(benzyloxy)-4-methoxyphenyl)chromane

(R)-7-(benzyloxy)-3-(2-(benzyloxy)-4-methoxyphenyl)chromane

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: lead(II,IV) oxide / benzene / 3 h / 85 °C
2: palladium 10% on activated carbon; hydrogen / ethanol
3: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
C32H30O6

C32H30O6

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: palladium 10% on activated carbon; hydrogen / ethanol
2: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
C18H18O6

C18H18O6

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
With potassium carbonate In ethyl acetate at 20℃; for 5h;112 mg
2-(benzyloxy)-4-methoxy-1-((E)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)vinyl)benzene

2-(benzyloxy)-4-methoxy-1-((E)-2-(((1R,2S)-2-phenylcyclohexyl)oxy)vinyl)benzene

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: diethyl ether / 0.17 h / -78 °C
1.2: 20 °C
2.1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 2.17 h / -78 °C
3.1: lead(II,IV) oxide / benzene / 3 h / 85 °C
4.1: palladium 10% on activated carbon; hydrogen / ethanol
5.1: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
C19H22O5
1019848-76-0

C19H22O5

medicarpin
32383-76-9

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: diethyl ether / 0.17 h / -78 °C
1.2: 20 °C
2.1: triethylsilane; boron trifluoride diethyl etherate / dichloromethane / 2.17 h / -78 °C
3.1: lead(II,IV) oxide / benzene / 3 h / 85 °C
4.1: palladium 10% on activated carbon; hydrogen / ethanol
5.1: potassium carbonate / ethyl acetate / 5 h / 20 °C
View Scheme
C20H27ClO2Si

C20H27ClO2Si

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: (S)-2-(fluorodiphenylmethyl)pyrrolidine; 4-nitro-benzoic acid; tetrabutyl ammonium fluoride; sodium dihydrogenphosphate / dichloromethane; tetrahydrofuran / 16 h / -40 °C
2.1: sodium tetrahydroborate / methanol / 0 °C
3.1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 20 °C
4.1: lead(II,IV) oxide; acetic acid / benzene / 3 h / 85 °C
4.2: 20 °C
4.3: 20 °C
View Scheme
2-benzyloxyl-4-methoxyphenylacetaldehyde

2-benzyloxyl-4-methoxyphenylacetaldehyde

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: (S)-2-(fluorodiphenylmethyl)pyrrolidine; 4-nitro-benzoic acid; tetrabutyl ammonium fluoride; sodium dihydrogenphosphate / dichloromethane; tetrahydrofuran / 16 h / -40 °C
2.1: sodium tetrahydroborate / methanol / 0 °C
3.1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 20 °C
4.1: lead(II,IV) oxide; acetic acid / benzene / 3 h / 85 °C
4.2: 20 °C
4.3: 20 °C
View Scheme
(S)-5-(benzyloxy)-2-(2-(2-(benzyloxy)-4-methoxyphenyl)-3-hydroxypropyl)phenol

(S)-5-(benzyloxy)-2-(2-(2-(benzyloxy)-4-methoxyphenyl)-3-hydroxypropyl)phenol

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 20 °C
2.1: lead(II,IV) oxide; acetic acid / benzene / 3 h / 85 °C
2.2: 20 °C
2.3: 20 °C
View Scheme
C30H28O5

C30H28O5

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: sodium tetrahydroborate / methanol / 0 °C
2.1: triphenylphosphine; diethylazodicarboxylate / tetrahydrofuran / 0 - 20 °C
3.1: lead(II,IV) oxide; acetic acid / benzene / 3 h / 85 °C
3.2: 20 °C
3.3: 20 °C
View Scheme
C30H28O4

C30H28O4

A

medicarpin
32383-76-9

medicarpin

B

medicarpin
33983-39-0

medicarpin

Conditions
ConditionsYield
Stage #1: C30H28O4 With lead(II,IV) oxide; acetic acid In benzene at 85℃; for 3h;
Stage #2: With 10 wt% Pd(OH)2 on carbon; hydrogen In tetrahydrofuran; ethanol at 20℃;
Stage #3: With potassium carbonate In ethyl acetate at 20℃; Overall yield = 49 %; Overall yield = 13 mg; enantioselective reaction;
A n/a
B n/a
medicarpin
32383-76-9

medicarpin

dimethylallyl diphosphate
358-72-5

dimethylallyl diphosphate

licoagrocarpin

licoagrocarpin

Conditions
ConditionsYield
With maackiain-4-dimethylallyltransferase from Psoralea corylifolia; magnesium chloride In aq. buffer at 30℃; for 1h; pH=9; Enzymatic reaction; regioselective reaction;
medicarpin
32383-76-9

medicarpin

uridine-5'-diphosphoglucose
952585-00-1

uridine-5'-diphosphoglucose

medicarpin 3‐O‐β‐D‐glucoside

medicarpin 3‐O‐β‐D‐glucoside

Conditions
ConditionsYield
With TcCGT1-C-glycosyltransferase from Trolliuschinensisuridine in complex with uridine diphosphate In aq. phosphate buffer at 30℃; for 2h; pH=8; Enzymatic reaction;
medicarpin
32383-76-9

medicarpin

dimethylallyl diphosphate
358-72-5

dimethylallyl diphosphate

(-)-3-O-isoprenylmedicarpin

(-)-3-O-isoprenylmedicarpin

Conditions
ConditionsYield
With recombinant O-prenyltransferase from Antrodia camphorata In aq. buffer at 37℃; for 12h; pH=7; Enzymatic reaction;

32383-76-9Relevant academic research and scientific papers

A general asymmetric route to enantio-enriched isoflavanes via an organocatalytic annulation of o-quinone methides and aldehydes

Zhang, Jian,Zhang, Shuangzhan,Yang, Huixin,Zhou, Ding,Yu, Xueting,Wang, Wei,Xie, Hexin

supporting information, p. 2407 - 2411 (2018/05/24)

Reported herein is a general approach to optically active isoflavanes based on a chiral amine-catalyzed [4 + 2] asymmetric annulation of o-quinone methides and aldehydes. A number of naturally occurring isoflavanes, including equol, sativan, isosativan, v

Unified total syntheses of (-)-medicarpin, (-)-sophoracarpan a, and (±)-kushecarpin a with some structural revisions

Feng, Zhen-Gao,Bai, Wen-Ju,Pettus, Thomas R. R.

, p. 1864 - 1867 (2015/02/19)

The total syntheses of medicarpin, sophoracarpan A, and kushecarpin A from a common intermediate are achieved by using ortho- and para-quinone methide chemistry. Additionally, the relative stereochemistry of sophoracarpan A and B have been reassigned.

Synthesis, optical resolution, absolute configuration, and osteogenic activity of cis-pterocarpans

Goel, Atul,Kumar, Amit,Hemberger, Yasmin,Raghuvanshi, Ashutosh,Jeet, Ram,Tiwari, Govind,Knauer, Michael,Kureel, Jyoti,Singh, Anuj K.,Gautam, Abnish,Trivedi, Ritu,Singh, Divya,Bringmann, Gerhard

, p. 9583 - 9592 (2013/01/16)

A convenient synthesis of natural and synthetic pterocarpans was achieved in three steps. Optical resolution of the respective enantiomers was accomplished by analytical and semi-preparative HPLC on a chiral stationary phase. For medicarpin and its synthetic derivative 9-demethoxymedicarpin, the absolute configuration was confirmed by a combination of experimental LC-ECD coupling and quantum-chemical ECD calculations. (-)-Medicarpin and (-)-9-demethoxymedicarpin are both 6aR,11aR-configured, and consequently the corresponding enantiomers, (+)-medicarpin and (+)-9-demethoxymedicarpin, possess the 6aS,11aS-configuration. A comparative mechanism study for osteogenic (bone forming) activity of medicarpin (racemic versus enantiomerically pure material) revealed that (+)-(6aS,11aS)-medicarpin (6a) significantly increased the bone morphogenetic protein-2 (BMP2) expression and the level of the bone-specific transcription factor Runx-2 mRNA, while the effect was opposite for the other enantiomer, (-)-(6aR,11aR)-medicarpin (6a), and for the racemate, (±)-medicarpin, the combined effect of both the enantiomers on transcription levels was observed. The Royal Society of Chemistry 2012.

Catalytic specificity of pea O-methyltransferases suggests gene duplication for (+)-pisatin biosynthesis

Akashi, Tomoyoshi,VanEtten, Hans D.,Sawada, Yuji,Wasmann, Catherine C.,Uchiyama, Hiroshi,Ayabe, Shin-ichi

, p. 2525 - 2530 (2007/10/03)

S-adenosyl-l-methionine: 2-hydroxyisoflavanone 4′-O-methyltransferase (HI4′OMT) methylates 2,7, 4′-trihydroxyisoflavanone to produce formononetin, an essential intermediate in the synthesis of isoflavonoids with methoxy or methylenedioxy groups at carbon 4′ (isoflavone numbering). HI4′OMT is highly similar (83% amino acid identity) to (+)-6a-hydroxymaackiain 3-O-methyltransferase (HMM), which catalyzes the last step of (+)-pisatin biosynthesis in pea. Pea contains two linked copies of HMM with 96% amino acid identity. In this report, the catalytic activities of the licorice HI4′OMT protein and of extracts of Escherichia coli containing the pea HMM1 or HMM2 protein are compared on 2,7,4′-trihydroxyisoflavanone and enantiomers of 6a-hydroxymaackiain. All these enzymes produced radiolabelled 2,7-dihydroxy-4′-methoxyisoflavanone or (+)-pisatin from 2,7,4′-trihydroxyisoflavanone or (+)-6a-hydroxymaakiain when incubated with [methyl-14C]-S-adenosyl-l-methionine. No product was detected when (-)-6a-hydroxymaackiain was used as the substrate. HI4′OMT and HMM1 showed efficiencies (relative Vmax/Km) for the methylation of 2,7,4′-trihydroxyisoflavanone 20 and 4 times higher than for the methylation of (+)-6a-hydroxymaackiain, respectively. In contrast, HMM2 had a higher Vmax and lower Km on (+)-6a-hydroxymaackiain, and had a 67-fold higher efficiency for the methylation of (+)-6a-hydroxymaackiain than that for 2,7,4′-trihydroxyisoflavanone. Among the 15 sites at which HMM1 and HMM2 have different amino acid residues, 11 of the residues in HMM1 are the same as found in HI4′OMTs from three plant species. Modeling of the HMM proteins identified three or four putative active site residues responsible for their different substrate preferences. It is proposed that HMM1 is the pea HI4′OMT and that HMM2 evolved by the duplication of a gene encoding a general biosynthetic enzyme (HI4′OMT).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 32383-76-9